JERUSALEM, June 4, 2012 /PRNewswire/ --
Oramed Pharmaceuticals (OTCBB: ORMP.OB), a developer of oral delivery systems, announced today that its abstract, "Concomitant oral insulin and exenatide therapies significantly curb postprandial glucose in pigs," which reports on the impact of its oral insulin capsule (ORMD-0801) delivered in combination with its oral exenatide capsule (ORMD-0901), has been accepted for presentation at the 72 nd Scientific Sessions of the American Diabetes Association (ADA). The work to be presented assessed the safety and effectiveness of a combination of oral insulin and oral exenatide treatments delivered to pigs prior to food intake. The drug combination resulted in significantly improved blood glucose regulation when compared to administration of each drug separately. Dr. Miriam Kidron, Chief Scientific Officer at Oramed Pharmaceuticals, will be presenting the poster on Sunday, June 10, 2012, at 11:30am-1:30pm (EDT).
For additional information on the upcoming ADA conference, please visit their website: http://professional.diabetes.org/Default.aspx
About Oramed PharmaceuticalsOramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials, and with its GLP-1 analog capsule, currently entering Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem. For more information, the content of which is not part of this press release, please visit http://www.oramed.com Company and Investor Relations Contact: Aviva Sherman USA: +1-646-240-4193 Int'l: +972-2-566-0001 +972-54-792-4438 E-mail: email@example.com SOURCE Oramed Pharmaceuticals